Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06174298 Recruiting - Infertility Clinical Trials

The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes

Start date: March 20, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to test the effect of granulocyte colony-stimulating factor (G-CSF, A.K.A. Filgrastim) in infertility patients undergoing in vitro fertilization (IVF) treatment. The main question it aims to answer is: Can in vitro fertilization-embryo transfer (IVF-ET) outcomes be improved by supplementing the transfer media with Granulocyte colony-stimulating factor (GCSF)? Participants will undergo their embryo transfer as per the normal clinic protocol but will be randomized to either receive the standard embryo transfer media or the GCSG-supplemented transfer media. Researchers will compare the GCSF and standard transfer media groups to see if clinical outcomes are improved (i.e., implantation rate, pregnancy, clinical pregnancy rate, live birth rate).

NCT ID: NCT06173986 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Start date: January 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with anti-PD-1 therapy in patients diagnosed with locally advanced, unresectable esophageal cancer.

NCT ID: NCT06173531 Recruiting - Clinical trials for Hyperphagia in Prader-Willi Syndrome

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Start date: November 27, 2023
Phase: Phase 3
Study type: Interventional

12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)

NCT ID: NCT06173518 Recruiting - Clinical trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Start date: November 16, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL)

NCT ID: NCT06173505 Recruiting - Clinical trials for Nonsquamous Non-small Cell Lung Cancer

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Start date: December 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).

NCT ID: NCT06173362 Recruiting - Clinical trials for Stage IV Prostate Cancer AJCC v8

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Start date: November 9, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation and lower the body's immune response. Researchers want to compare the side effects of standard of care (SOC) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.

NCT ID: NCT06173167 Recruiting - Dental Diseases Clinical Trials

Clinical Evaluation of Full Contour Zirconia Chairside CAD/CAM Crowns

Start date: January 8, 2024
Phase: N/A
Study type: Interventional

This investigation will be a randomized, prospective, longitudinal clinical trial to study the clinical performance of a new monolithic, zirconia material with shade, translucency and material graduation for chairside CAD/CAM crowns. The restorations will be luted either with a self-adhesive luting material or a conventional cement. The crowns will be evaluated for a period of two years.

NCT ID: NCT06172205 Recruiting - Chemotherapy Effect Clinical Trials

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Start date: July 1, 2023
Phase: Phase 3
Study type: Interventional

This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.

NCT ID: NCT06172062 Recruiting - Clinical trials for Laparoscopic Pancreaticoduodenectomy

Establishment and Application of an Artificial Intelligence Algorithm for Automatic Identification of Intraoperative Bleeding During Laparoscopic Pancreaticoduodenectomy

Start date: July 20, 2023
Phase:
Study type: Observational

Surgeons will label surgical videos of laparoscopic pancreaticoduodenectomy with bleeding information from multicenter. The labeled surgical video will be used as training material to train the algorithmic model so as to build an artificial intelligence algorithm that can automatically identify intraoperative bleeding in this surgery. Then, we will test the performance capability of the algorithm.

NCT ID: NCT06170996 Recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder (ADHD)

Internet-Assisted Behavioral Parent Training Intervention for Children With Attention Deficit Hyperactivity Disorder

Start date: September 12, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the effectiveness of an Internet-Assisted behavioral parent training intervention on children's ADHD symptoms and children's and parents' mental health status.